+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients



Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients



British Journal of Clinical Pharmacology 71(4): 556-565



Pharmacogenetics can be used as a tool for stratified pharmacological therapy in cardiovascular medicine. We investigated whether a predefined combination of the Arg389Gly polymorphism in the adrenergic β(1) -receptor gene (ADRB1) and the Gln27Glu polymorphism in the adrenergic β(2) -receptor gene (ADRB2) could predict survival in carvedilol- and metoprolol-treated chronic heart failure (HF) patients. Five hundred and eighty-six HF patients (carvedilol n= 82, metoprolol n= 195) were genotyped for ADRB1 Arg389Gly (rs1801253) and ADRB2 Gln27Glu (rs1042714). The end-point was all-cause mortality, and median follow-up time was 6.7 years. Patients were classified into two functional genotype groups: group 1 combination of Arg389-homozygous and Gln27-carrier (46%) and group 2 any other genotype combination (54%). Results were fitted in two multivariate Cox models. There was a significant interaction between functional genotype group and carvedilol treatment (adjusted(1) P= 0.033, adjusted(2) P= 0.040). Patients treated with carvedilol had shorter survival in functional genotype group 1 (P= 0.004; adjusted(1) hazard ratio (HR) 2.67, 95% CI 1.27, 5.59, P= 0.010; adjusted(2) HR 2.05, 95% CI 1.06, 3.95, P= 0.033). There was no interaction between genotype group and metoprolol treatment (P= 0.61), and there was no difference in overall survival between genotype groups (P= 0.69). A combination of ADRB1 Arg389-homozygous and ADRB2 Gln27-carrier in HF patients treated with carvedilol was associated with a two-fold increase in mortality relative to all other genotype combinations. There was no difference in survival in metoprolol-treated HF patients between genotype groups. Patients in genotype group 1 may benefit more from metoprolol than carvedilol treatment.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051682170

Download citation: RISBibTeXText

PMID: 21395649

DOI: 10.1111/j.1365-2125.2010.03868.x


Related references

Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovascular Drugs and Therapy 24(1): 49-60, 2010

Beta-2 adrenergic receptors polymorphisms influence the effects of carvedilol in the patients with chronic heart failure. Circulation 108(17 Suppl.): IV-485-IV-486, 2003

Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. Journal of the American College of Cardiology 52(8): 644-651, 2008

Association of T190C polymorphism of β3 adrenergic receptor gene with response to carvedilol in patients with chronic heart failure. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 32(1): 101-104, 2015

Serum autoantibodies against the cardiac beta(1)-adrenergic receptor in patients with chronic heart failure: clinical characteristics and response to carvedilol. Zhonghua Xin Xue Guan Bing Za Zhi 35(7): 599-602, 2007

Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenetics and Genomics 15(3): 137-142, 2005

Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. American Journal of Medicine 117(7): 451-458, 2004

Association of Genetic Polymorphisms in the Beta-1 Adrenergic Receptor with Recovery of Left Ventricular Ejection Fraction in Patients with Heart Failure. Journal of Cardiovascular Translational Research 12(4): 280-289, 2019

Relationships between carvedilol stereoisomer plasma concentrations and beta-receptor occupancies in subjects with chronic heart failure in the Multicenter Oral Carvedilol Heart Failure Assessment trial. European Heart Journal 17(ABSTR Suppl. ): 135, 1996

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. New England Journal of Medicine 334(21): 1349-1355, 1996

Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure. Journal of the American College of Cardiology 36(5): 1612-1618, 2000

Relationship between beta-1 adrenergic receptor polymorphisms and the response to beta-blockers in patients with heart failure. Circulation 104(17 Suppl.): II 661-II 662, 2001

Polymorphisms of the beta-2 adrenergic receptors may influence the effects of beta-blocker therapy in the patients with chronic heart failure. European Heart Journal 24(Abstract Suppl.): 711, August-September, 2003

Beta-2 adrenergic receptor gene polymorphisms Gln27Glu, Arg16Gly in patients with heart failure. Bmc Cardiovascular Disorders 9: 50, 2009

Polymorphisms of the beta-2 adrenergic receptor affect exercise capacity in patients with heart failure. Journal of Investigative Medicine 44(7): 394, 1996